Compare Novartis AG (NVS) vs Snowflake Inc (SNOW) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Snowflake (SNOW) trades at $335.50, down 0.5% on the day, but maintains strong technical momentum with bullish moving averages and support at $331. The company demonstrates accelerating revenue growth, with Q2 2026 EPS beating expectations at $0.62 versus $0.45, and product revenue up 37% year-over-year. Recent news highlights AI-driven customer expansion and improved guidance, with the stock gaining 67% year-to-date in 2026.

Snowflake presents a growth-oriented investment case with robust AI adoption and enterprise expansion driving revenue acceleration. However, negative profitability metrics and elevated valuation multiples (P/S 21.25, P/B 55.06) pose significant risks. Analyst consensus remains strongly bullish with a $430 price target, but investors must weigh growth potential against persistent losses and competitive pressures in cloud analytics.